SOURCE: BIOLASE Technology, Inc.
IRVINE, CA--(Marketwire - May 4, 2012) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced the introduction of the EPIC 10™, the next generation of BIOLASE's Total Diode Solution. The EPIC 10 is being demonstrated at CDA Presents: Anaheim 2012, the California Dental Association's annual tradeshow, being held May 3-5 at the Anaheim Convention Center in Anaheim, CA, and several other concurrent and upcoming dental industry events. EPIC 10 is not yet available for sale in the U.S. as it is pending 510k clearance from the Food and Drug Administration ("FDA").
This next generation, diode soft-tissue laser will have the shortest pulse available in the market today. Short pulses are known to cause less thermal damage in tissue and produce cleaner cuts. In addition, the EPIC 10 will have a built-in battery for a full day of operation and will be used as a design platform to build more powerful versions with different combinations of laser wavelengths.
Federico Pignatelli, Chairman and CEO, said, "The EPIC 10 represents yet another important innovation at BIOLASE and an evolution of diode soft-tissue dental laser technology. The ability to combine 15 of the most commonly performed soft-tissue procedures, including 20-minute laser whitening and temporary oral pain relief, in one device is a true innovation for our customers and their patients. The BIOLASE engineering and marketing teams continue to lead the dental technology community in advancing laser technology with a focus on providing new tools to improve both the clinical results and the return-on-investment of dental practices. The EPIC 10 is a great example of such combined focus."
The EPIC 10 features a 940nm wavelength with 10 watts of real power as well as an intuitive procedure-based graphical touchscreen. It also uses BIOLASE's proprietary ComfortPulse™ control technology that helps to prevent potential tissue damage and keeps patients comfortable by avoiding pain-inducing heat buildup at the surgical site.
Neither EPIC 10, nor any claims of efficacy attached to it, are yet cleared by the FDA. There is no guarantee that the FDA will approve the device, nor any timeframe upon which such approval may occur.
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate 285 patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,000 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.
For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by BIOLASE management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and BIOLASE undertakes no obligation to update such statements.